Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and LeMaitre Vascular (LMAT) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Right now, Haleon PLC Sponsored ADR is sporting a Zacks Rank of #2 (Buy), while LeMaitre Vascular has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assur ...

Acadia Pharmaceuticals (ACAD) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD's commercial portfolio comprises two marketed drugs — Nuplazid (pimavanserin) and Daybue (trofinetide). Revenues generated from the sales of Nuplazid are the majority contributor to Acadia's top line. In the first quarter of 2024, Nuplazid sales increased 10% year over year to $129.9 million, driven by improvem ...

Continued good momentum despite China declining low-single digit due to a tough comparative Volume /mix Pain Relief – Double digit decline mainly due to challenging Fenbid comparative in China in Q1 2023 when revenue more than doubled Strong Q1 organic profit growth 23.1% 24.2% +220bps (30)bps (80)bps 12 1. Reconciliation of IFRS to Adjusted results can be found in the Appendix 2. Net M&A: disposal of Lamisil and includes the impact of Manufacturing Service Agreements (MSAs) 3. Refers to Organic. Definition ...

As usual, we will take you through some prepared remarks before opening the call to Q&A. For those listening to our webcast, whoÂ'd like to ask a question, please use the dial-in details on Page 3 of todayÂ's release. Also, while the focus today is on revenue performance, weÂ've also provided group profit and margin detail on both a reported and an adjusted basis, with a full reconciliation, including one for organic revenue growth in the appendix. As a reminder and for information, we do not intend to prov ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Annual Report and Form 20-F 2023 Haleon at a glance | We are a global leader in the growing consumer healthcare market: | | | | | | | --- | --- | --- | --- | --- | --- | | £190bn | 5 9 £11.3bn | | | | | | Market1 | Global categories1 Power Brands Revenue | | | | | | Our purpose: | To deliver better everyday health with humanity | | | | | | Our strategy: | Our strategy is designed to leverage our portfolio and capabilities | | | | | | | and has four key pillars: | | | | | | | 1 2 3 4 | | | | | | | Increase C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File ...

Financial Data and Key Metrics - Gross margin increased by 70 basis points in Q4, driven by easing inflationary pressures and pricing strategies [24] - The company ended the year with a strong cash position of £1 billion, allowing it to pay back a $700 million bond due in March and distribute dividends [11] - Operating profit grew nearly three points ahead of the rate of sales growth in 2023, with a 60 basis points margin improvement [45][69] Business Line Performance - Respiratory health division saw strong growth in Q4, with a 7.5% increase in the back half of the year, driven by geographic diversity and product portfolio strength [64][65] - Oral health segment performed well, with strong growth in Sensodyne and other brands, supported by innovation and pricing strategies [104][131] - VMS (Vitamins, Minerals, and Supplements) showed improvement, particularly with Centrum and Caltrate, driven by clinical studies and marketing support [60][61] Market Performance - In China, the OTC business saw significant demand due to COVID-related restrictions being lifted, with strong performance in Q1 and Q2 expected [22][34] - North America experienced a challenging environment in respiratory health, with flat performance in the back half of the year, while other regions like Central Eastern Europe, Japan, and Turkey saw higher growth [64][65] - India saw high single-digit sales growth, with Sensodyne leading with double-digit growth, despite some disruptions from the transition from Hindustan Unilever [88][89] Strategic Direction and Industry Competition - The company is focusing on innovation, with 67 new product launches in 2023, including Sensodyne Clinical White and other oral health products [15][121] - A&P (Advertising and Promotion) spend is being actively managed, with a focus on investing in growth areas and optimizing returns, particularly in oral health and VMS [2][16][48] - The company is targeting a 50-50 split between volume and price growth in the long term, with 2024 being a stepping stone towards this goal [50][137] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the 4% to 6% sales growth guidance for 2024, with organic profit expected to grow ahead of sales growth [21][28] - The company is managing inflationary pressures and expects gross margin to continue growing ahead of sales growth, supported by pricing and productivity programs [24][25] - The respiratory health market is expected to normalize, with fluctuations of plus or minus 0.5% to 1% in extreme seasons [65] Other Important Information - The company is actively managing its portfolio, with divestments and potential bolt-on acquisitions to strengthen its business [75][146] - A £500 million share buyback program is planned for 2024, with flexibility to execute it through open market purchases or placings with GSK and Pfizer [86][145] - The company is targeting a medium-term leverage ratio of around 2.5x, supported by strong cash generation and debt reduction efforts [129][101] Q&A Session Summary Question: Net benefit from savings in 2025 and A&P spend drivers - The company did not provide specific net benefit figures for 2025 but mentioned that productivity programs will provide a tailwind for 2024 [3] - A&P spend in 2023 was 80 basis points of potential sales, driven by rationalization post-GSK and reduced spend in the US respiratory market [1][2] Question: Volume performance in EMEA and LatAm - Volume declines in EMEA and LatAm were noted, particularly in Latin America, linked to hyperinflation in Argentina [128][123] Question: Respiratory health performance in Q4 - Respiratory health saw strong growth in Q4, driven by geographic diversity and product portfolio strength, with no significant one-offs or inventory discrepancies [64][65] Question: Innovation and R&D spend - R&D spend as a percentage of sales declined due to efficiencies and accounting changes, but the company remains committed to innovation, with 67 new product launches in 2023 [7][121] Question: Share buyback and capital allocation - The company plans a £500 million share buyback in 2024, with flexibility to execute it through open market purchases or placings with GSK and Pfizer [86][145] Question: Pricing and volume growth in 2024 - The company expects pricing to contribute more to growth than volume in 2024, with a long-term goal of a 50-50 split between the two [50][137]

2023 Full year results February 2024 These forward-looking statements and views may be based on a number of assumptions and, by their nature, involve known and unknown risks, uncertainties and other factors because they relate to events and depend on circumstances that may or may not occur in the future and/or are beyond Haleon's control or precise estimate. Such risks, uncertainties and other factors that could cause Haleon's actual results, performance or achievements to differ materially from those in th ...

Adjusting Items include the following: • Transaction related costs: Transaction related accounting or other adjustments related to significant acquisitions including deal costs and other pre-acquisition costs when there is certainty that an acquisition will complete. It also includes costs of registering and issuing debt and equity securities and the effect of inventory revaluations on acquisitions. Free cash flow Free cash flow is calculated as net cash inflow from operating activities plus cash inflows fr ...